Literature DB >> 9286231

A prospective study of prognostic value of type IV collagenase activity in colorectal cancer tissue.

S Ambiru1, M Miyazaki, H Ito, K Nakagawa, H Shimizu, Y Nukui, S Nozawa, A Okuno, H Yoshitomi, N Nakajima.   

Abstract

The purpose of this prospective study was to evaluate the prognostic value of the type IV collagenase (IVase) activity in colorectal cancer tissue on disease-free and overall survival in 31 colorectal cancer patients. The clinicopathologic factors studied for prognostic value were age, tumor location, tumor differentiation, preoperative serum levels of carcinoembryonic antigen, Dukes' stage, and IVase activity in colorectal cancer tissue. IVase activities in colorectal cancer tissue were significantly higher in the group of patients with recurrences than in the group without recurrences (P = 0.019). Patients with high IVase activity in colorectal cancer tissue had a significantly shorter disease-free survival (P = 0.0016) and overall survival (P = 0.022) time than those with low IVase activity. Univariate and multivariate analysis showed that significant prognostic factors for disease-free survival were Dukes' stage (P = 0.029, P = 0.046, respectively) and IVase activity status (P = 0.0016, P = 0.0026, respectively). With respect to overall survival, only IVase activity status provided significant predictive value in multivariate analysis (P = 0.041). This prospective study suggests that IVase activity is a valuable prognostic factor in colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286231     DOI: 10.1023/a:1018801229372

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases.

Authors:  O A Alvarez; D F Carmichael; Y A DeClerck
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

2.  The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.

Authors:  W G Stetler-Stevenson; H C Krutzsch; M P Wacher; I M Margulies; L A Liotta
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

3.  Direct measurement of neutral collagenase activity in homogenates from baboon and human liver.

Authors:  K Maruyama; L Feinman; I Okazaki; C S Lieber
Journal:  Biochim Biophys Acta       Date:  1981-03-13

4.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

5.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; S B Gruber; R J Muschel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma.

Authors:  T Nakayama; M Watanabe; T Katsumata; T Teramoto; M Kitajima
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

7.  Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer.

Authors:  I F al-Sheneber; H R Shibata; J Sampalis; S Jothy
Journal:  Cancer       Date:  1993-03-15       Impact factor: 6.860

8.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.

Authors:  B Davies; J Waxman; H Wasan; P Abel; G Williams; T Krausz; D Neal; D Thomas; A Hanby; F Balkwill
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

9.  Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study.

Authors:  M Ponz de Leon; M Sant; A Micheli; C Sacchetti; C Di Gregorio; R Fante; G Zanghieri; G Melotti; G Gatta
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

10.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Authors:  H E Mulcahy; M J Duffy; D Gibbons; P McCarthy; N A Parfrey; D P O'Donoghue; K Sheahan
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

View more
  1 in total

1.  Tumour markers of prognosis in colorectal cancer.

Authors:  H L McLeod; G I Murray
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.